A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients

Carlos Gustavo de Moraes, Mitra Sehi, David Greenfield, Yun S. Chung, Robert Ritch, Jeffrey M. Liebmann

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

PURPOSE. The purpose of our study is to develop and validate a model to predict visual field (VF) outcomes in patients with treated glaucoma. METHODS. Data from 587 eyes with treated glaucoma evaluated in a cohort were used to develop two equations to predict VF outcomes, one estimating the risk of progression (%) and another estimating the global rate of VF sensitivity change (decibels [dB]/year). These equations, which included variables associated with VF progression in a multivariable model, then were tested in another cohort (n = 62 eyes) followed for at least 4 years. Agreement, discrimination, and calibration of the model in the validation sample were assessed as main outcome measures. RESULTS. The mean difference between observed and predicted global rates of sensitivity change was 0.13 dB/year (95% confidence interval [CI] = 0.06 to 0.18 dB/year) and the mean difference between observed and predicted final VF mean deviation (MD) values was 0.37 dB (95% CI=0.00 to 0.75 dB). The predictive model had moderate discriminative ability to estimate VF progression in the independent sample (c-index of 0.78, 95% CI = 0.59 to 0.97). CONCLUSIONS. To our knowledge, this is the first attempt to generate and validate a risk model for patients with treated glaucoma. The prediction model showed moderate accuracy in estimating future VF outcomes in an independent glaucoma population, and may be useful for the objective assessment of risk of progressive VF loss.

Original languageEnglish
Pages (from-to)2702-2707
Number of pages6
JournalInvestigative Ophthalmology and Visual Science
Volume53
Issue number6
DOIs
StatePublished - May 1 2012

Fingerprint

Visual Fields
Glaucoma
Confidence Intervals
Aptitude
Calibration
Outcome Assessment (Health Care)
Population

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients. / de Moraes, Carlos Gustavo; Sehi, Mitra; Greenfield, David; Chung, Yun S.; Ritch, Robert; Liebmann, Jeffrey M.

In: Investigative Ophthalmology and Visual Science, Vol. 53, No. 6, 01.05.2012, p. 2702-2707.

Research output: Contribution to journalArticle

de Moraes, Carlos Gustavo ; Sehi, Mitra ; Greenfield, David ; Chung, Yun S. ; Ritch, Robert ; Liebmann, Jeffrey M. / A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients. In: Investigative Ophthalmology and Visual Science. 2012 ; Vol. 53, No. 6. pp. 2702-2707.
@article{a44a1809e73f4336af0f9c3fb0784a25,
title = "A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients",
abstract = "PURPOSE. The purpose of our study is to develop and validate a model to predict visual field (VF) outcomes in patients with treated glaucoma. METHODS. Data from 587 eyes with treated glaucoma evaluated in a cohort were used to develop two equations to predict VF outcomes, one estimating the risk of progression ({\%}) and another estimating the global rate of VF sensitivity change (decibels [dB]/year). These equations, which included variables associated with VF progression in a multivariable model, then were tested in another cohort (n = 62 eyes) followed for at least 4 years. Agreement, discrimination, and calibration of the model in the validation sample were assessed as main outcome measures. RESULTS. The mean difference between observed and predicted global rates of sensitivity change was 0.13 dB/year (95{\%} confidence interval [CI] = 0.06 to 0.18 dB/year) and the mean difference between observed and predicted final VF mean deviation (MD) values was 0.37 dB (95{\%} CI=0.00 to 0.75 dB). The predictive model had moderate discriminative ability to estimate VF progression in the independent sample (c-index of 0.78, 95{\%} CI = 0.59 to 0.97). CONCLUSIONS. To our knowledge, this is the first attempt to generate and validate a risk model for patients with treated glaucoma. The prediction model showed moderate accuracy in estimating future VF outcomes in an independent glaucoma population, and may be useful for the objective assessment of risk of progressive VF loss.",
author = "{de Moraes}, {Carlos Gustavo} and Mitra Sehi and David Greenfield and Chung, {Yun S.} and Robert Ritch and Liebmann, {Jeffrey M.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1167/iovs.11-7900",
language = "English",
volume = "53",
pages = "2702--2707",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "6",

}

TY - JOUR

T1 - A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients

AU - de Moraes, Carlos Gustavo

AU - Sehi, Mitra

AU - Greenfield, David

AU - Chung, Yun S.

AU - Ritch, Robert

AU - Liebmann, Jeffrey M.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - PURPOSE. The purpose of our study is to develop and validate a model to predict visual field (VF) outcomes in patients with treated glaucoma. METHODS. Data from 587 eyes with treated glaucoma evaluated in a cohort were used to develop two equations to predict VF outcomes, one estimating the risk of progression (%) and another estimating the global rate of VF sensitivity change (decibels [dB]/year). These equations, which included variables associated with VF progression in a multivariable model, then were tested in another cohort (n = 62 eyes) followed for at least 4 years. Agreement, discrimination, and calibration of the model in the validation sample were assessed as main outcome measures. RESULTS. The mean difference between observed and predicted global rates of sensitivity change was 0.13 dB/year (95% confidence interval [CI] = 0.06 to 0.18 dB/year) and the mean difference between observed and predicted final VF mean deviation (MD) values was 0.37 dB (95% CI=0.00 to 0.75 dB). The predictive model had moderate discriminative ability to estimate VF progression in the independent sample (c-index of 0.78, 95% CI = 0.59 to 0.97). CONCLUSIONS. To our knowledge, this is the first attempt to generate and validate a risk model for patients with treated glaucoma. The prediction model showed moderate accuracy in estimating future VF outcomes in an independent glaucoma population, and may be useful for the objective assessment of risk of progressive VF loss.

AB - PURPOSE. The purpose of our study is to develop and validate a model to predict visual field (VF) outcomes in patients with treated glaucoma. METHODS. Data from 587 eyes with treated glaucoma evaluated in a cohort were used to develop two equations to predict VF outcomes, one estimating the risk of progression (%) and another estimating the global rate of VF sensitivity change (decibels [dB]/year). These equations, which included variables associated with VF progression in a multivariable model, then were tested in another cohort (n = 62 eyes) followed for at least 4 years. Agreement, discrimination, and calibration of the model in the validation sample were assessed as main outcome measures. RESULTS. The mean difference between observed and predicted global rates of sensitivity change was 0.13 dB/year (95% confidence interval [CI] = 0.06 to 0.18 dB/year) and the mean difference between observed and predicted final VF mean deviation (MD) values was 0.37 dB (95% CI=0.00 to 0.75 dB). The predictive model had moderate discriminative ability to estimate VF progression in the independent sample (c-index of 0.78, 95% CI = 0.59 to 0.97). CONCLUSIONS. To our knowledge, this is the first attempt to generate and validate a risk model for patients with treated glaucoma. The prediction model showed moderate accuracy in estimating future VF outcomes in an independent glaucoma population, and may be useful for the objective assessment of risk of progressive VF loss.

UR - http://www.scopus.com/inward/record.url?scp=84861169932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861169932&partnerID=8YFLogxK

U2 - 10.1167/iovs.11-7900

DO - 10.1167/iovs.11-7900

M3 - Article

C2 - 22447872

AN - SCOPUS:84861169932

VL - 53

SP - 2702

EP - 2707

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 6

ER -